Exchange Traded Concepts LLC acquired a new stake in Crispr Therapeutics AG (NASDAQ:CRSP) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 894 shares of the company’s stock, valued at approximately $54,000.
Several other hedge funds have also recently bought and sold shares of the company. Nikko Asset Management Americas Inc. boosted its holdings in shares of Crispr Therapeutics by 48.4% in the third quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock valued at $113,846,000 after acquiring an additional 906,006 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Crispr Therapeutics by 19.6% in the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after acquiring an additional 121,176 shares during the period. Orbimed Advisors LLC acquired a new stake in shares of Crispr Therapeutics in the third quarter valued at approximately $21,167,000. Global Thematic Partners LLC boosted its holdings in shares of Crispr Therapeutics by 1.7% in the fourth quarter. Global Thematic Partners LLC now owns 350,386 shares of the company’s stock valued at $21,340,000 after acquiring an additional 5,764 shares during the period. Finally, Morgan Stanley boosted its holdings in shares of Crispr Therapeutics by 6.1% in the second quarter. Morgan Stanley now owns 284,984 shares of the company’s stock valued at $13,423,000 after acquiring an additional 16,361 shares during the period. 49.83% of the stock is owned by institutional investors and hedge funds.
Shares of CRSP stock opened at $54.75 on Friday. Crispr Therapeutics AG has a fifty-two week low of $29.34 and a fifty-two week high of $74.00. The stock has a market cap of $3.02 billion, a P/E ratio of -119.02 and a beta of 3.20. The business has a fifty day simple moving average of $63.18 and a 200-day simple moving average of $52.50. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The business had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. On average, sell-side analysts anticipate that Crispr Therapeutics AG will post 0.65 earnings per share for the current year.
Several research firms have recently weighed in on CRSP. BidaskClub downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. Oppenheimer upped their price target on Crispr Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a research note on Monday, November 25th. Zacks Investment Research cut Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. William Blair upgraded Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, November 19th. Finally, Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a research note on Friday, December 6th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the company. Crispr Therapeutics currently has a consensus rating of “Buy” and an average price target of $75.95.
In related news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total transaction of $390,000.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at $390,000. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, President Rodger Novak sold 33,618 shares of the stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. In the last 90 days, insiders sold 56,118 shares of company stock valued at $3,620,760. Company insiders own 21.40% of the company’s stock.
Crispr Therapeutics Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: What is a resistance level?
Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crispr Therapeutics AG (NASDAQ:CRSP).
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.